Cetuximab Adds No Benefit to First-Line Regimen for Metastatic Colorectal Cancer, Oslo University Study

Idsk -- MILAN (EGMN) – Cetuximab in combination with a continuous or intermittently administered Nordic FLOX regimen for the first-line treatment of metastatic colorectal cancer conferred no advantage over the chemotherapy regimen alone, the first results of the Nordic VII study show.